Rudnick Lab

Our laboratory is interested in elucidating the molecular signaling mechanisms of liver regeneration. In addition to liver mass being precisely regulated in proportion to body mass, this organ is also able to regenerate the anatomic and functional deficits incurred by many forms of injury or disease (e.g. toxin exposure, trauma, infection). We use rodent partial hepatectomy and other models to investigate the mechanisms responsible for this remarkable regenerative potential, and have focused our recent efforts on defining and investigating the functional relevance of extrahepatic signals that influence regulation of liver mass and regeneration. In addition, we began a translational line of investigation in which lessons learned about liver regeneration in this basic model are applied to analyses of human liver diseases. Such studies led us to identify a novel metabolomic marker of liver regeneration and evaluate its utility in predicting clinical outcomes in pediatric acute liver failure.

Principal investigator

David A. Rudnick, MD, PhD

Associate Professor of Pediatrics, Gastroenterology, Hepatology & Nutrition
Researcher, Developmental Biology

• Phone: 314-454-6173

 

Top areas of care: gastroenterology, nutrition, liver regeneration

Recent publications

• Juvenile polyposis syndrome in children: The impact of SMAD4 and BMPR1A mutations on clinical phenotype and polyp burden
  July 1, 2024
  Juvenile polyposis syndrome in children: The impact of SMAD4 and BMPR1A mutations on clinical phenotype and polyp burdenCohen, S., Yerushalmy-Feler, A., Rojas, I., Phen, C., Rudnick, D. A., Flahive, C. B., Erdman, S. H., Magen-Rimon, R., Copova, I., Attard, T., Latchford, A. & Hyer, W., Jul 2024, In: Journal of pediatric gastroenterology and nutrition. 79, 1, p. 161-167 7 p.Research output: Contribution to journal › Article › peer-review
• New Insights About Epigenetic Mechanisms That Influence Risk of Transgenerational Fatty Liver Disease
  January 1, 2024
  New Insights About Epigenetic Mechanisms That Influence Risk of Transgenerational Fatty Liver DiseaseRudnick, D. A., 2024, (Accepted/In press) In: CMGH.Research output: Contribution to journal › Editorial
• Neurological Improvement in a Patient with Cerebroretinal Microangiopathy with Calcifications and Cysts-1 Treated with Bevacizumab
  January 1, 2023
  Neurological Improvement in a Patient with Cerebroretinal Microangiopathy with Calcifications and Cysts-1 Treated with BevacizumabSharayah, S., Agner, S. C., Shinawi, M., Rudnick, D. & Mar, S., Jan 2023, In: Annals of Child Neurology. 31, 1, p. 52-55 4 p.Research output: Contribution to journal › Letter › peer-review
• An Update on Pediatric Acute Liver Failure: Emerging Understanding of the Impact of Immune Dysregulation and Novel Opportunities for Intervention
  August 1, 2022
  An Update on Pediatric Acute Liver Failure: Emerging Understanding of the Impact of Immune Dysregulation and Novel Opportunities for InterventionKulkarni, S., Chapin, C. A., Alonso, E. M. & Rudnick, D. A., Aug 2022, In: Clinics in Liver Disease. 26, 3, p. 461-471 11 p.Research output: Contribution to journal › Review article › peer-review
• Regulation of PGC1α Downstream of the Insulin Signaling Pathway Plays a Role in the Hepatic Proteotoxicity of Mutant α1-Antitrypsin Deficiency Variant Z
  July 1, 2022
  Regulation of PGC1α Downstream of the Insulin Signaling Pathway Plays a Role in the Hepatic Proteotoxicity of Mutant α1-Antitrypsin Deficiency Variant ZRudnick, D. A., Huang, J., Hidvegi, T., Chu, A. S., Hale, P., Munanairi, A., Dietzen, D. J., Cliften, P. F., Tycksen, E., Lutkewitte, A. J., Finck, B. N., Pak, S. C., Silverman, G. A. & Perlmutter, D. H., Jul 2022, In: Gastroenterology. 163, 1, p. 270-284 15 p.Research output: Contribution to journal › Article › peer-review